Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma

Kate Vandyke, Annie W S Chow, Sharon A. Williams, Luen B. To, Andrew C W Zannettino

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)


N-cadherin (cadherin 2, type 1, N-cadherin (neuronal); CDN2) is a homotypic adhesion molecule that is upregulated in breast, prostate and bladder cancer. Here we investigated the prognostic significance of upregulated N-cadherin expression in multiple myeloma (MM). Our results indicate that N-cadherin protein and gene expression is abnormally increased in trephine biopsies and CD38++/CD138+ plasma cells from MM patients, when compared with those of normal donors. In addition, levels of circulating N-cadherin were elevated in a subset of patients with MM (n = 81; mean: 14·50 ng/ml, range: 0-146·78 ng/ml), relative to age-matched controls (n = 27; mean: 2·66 ng/ml, range: 0-5·96 ng/ml), although this did not reach statistical significance. Notably, patients with abnormally high levels of N-cadherin (>6 ng/ml) had decreased progression-free survival (P = 0·036; hazard ratio: 1·94) and overall survival (P = 0·002; hazard ratio: 3·15), when compared with patients with normal N-cadherin levels (≤6 ng/ml). Furthermore, multivariate analyses revealed that the combination of N-cadherin levels and International Staging System (ISS) was a more powerful prognostic indicator than using ISS alone. Collectively, our studies demonstrate that circulating N-cadherin levels are a viable prognostic marker for high-risk MM patients.

Original languageEnglish
Pages (from-to)499-507
Number of pages9
JournalBritish Journal of Haematology
Issue number4
Publication statusPublished or Issued - May 2013


  • Multiple myeloma
  • N-cadherin
  • Prognostic marker, novel therapeutic target, ISS

ASJC Scopus subject areas

  • Hematology

Cite this